Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Heat Stable Rotavirus Vaccine (HSRV) is an oral, live-attenuated pentavalent vaccine designed to prevent rotavirus gastroenteritis, particularly in resource-limited settings. Developed by MSD Wellcome Trust Hilleman Laboratories, the vaccine utilizes the same five human-bovine reassortant rotavirus strains (G1, G2, G3, G4, and P[8]) found in Merck's RotaTeq. Its primary innovation is a lyophilized formulation that maintains potency at high temperatures (up to 45°C for several months), significantly reducing the need for a continuous cold chain. Clinical studies have demonstrated safety and immunogenicity comparable to existing vaccines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Heat Stable Rotavirus Vaccine (Merck & Co.).